ScreenerHero

RCKT Rocket Pharmaceuticals, Inc.

NAS · US · Healthcare · Biotechnology · rocketpharma.com
2.535USD+2.22%Mkt Cap: 278.28M $P/E: —

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases i…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap278.28M USD
Enterprise Value13.29M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-223.12M USD
Revenue/Share—
Last Price2.535 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees202
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.90
PEG—
EV/EBITDA-0.07
EV/Revenue—
P/S—
P/B0.74
EPS (TTM)-0.16
EPS (Forward)-1.30
52W Range
2.4204% of range5.450
52W High5.450 USD
52W Low2.420 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-80.49%
ROA-67.52%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-190.01M USD
CapEx (TTM)440.00K USD
FCF Margin—
FCF Yield30.95%
Net Debt-258.95M USD
Net Debt/EBITDA1.42
Balance Sheet
Debt/Equity0.09
Current Ratio9.24
Quick Ratio9.06
Book Value/Sh3.37 USD
Cash/Share2.58 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateJan 5, 2018
Splits
Last Split1:4
Split DateJan 5, 2018
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.854 USD
Upside (mean)+249.3%
Target Range3.000 USD – 15.00 USD
3.000+249.3% to mean15.00
# Analysts12
Ownership
Shares Out.109.77M
Float87.62M
Insiders3.18%
Institutions91.79%
Short Interest
Short Ratio10.3d
Short % Float16.58%
Short % Out.13.53%
Shares Short14.85M
Short (prev mo.)14.39M
Technical
SMA 503.348 (-24.3%)
SMA 2003.562 (-28.8%)
Beta0.50
S&P 52W Chg16.45%
Avg Vol (30d)1.70M
Avg Vol (10d)2.22M
Technical Indicators
RSI (14)29.8
MACD-0.2671
MACD Signal-0.2201
MACD Hist.-0.0470
BB Upper3.978 USD
BB Middle3.025 USD
BB Lower2.072 USD
BB Width62.99%
ATR (14)0.1904 USD
Vol Ratio (20d)1.57x